Clinical Trials Logo

Triple Negative Breast Cancer clinical trials

View clinical trials related to Triple Negative Breast Cancer.

Filter by:

NCT ID: NCT06318897 Recruiting - Clinical trials for Triple Negative Breast Cancer

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Start date: May 29, 2024
Phase: Phase 2
Study type: Interventional

To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.

NCT ID: NCT06299163 Recruiting - Endometrial Cancer Clinical Trials

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Start date: May 1, 2024
Phase: Phase 1
Study type: Interventional

This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.

NCT ID: NCT06281210 Recruiting - Breast Cancer Clinical Trials

Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery

BETTY-CRASY
Start date: December 11, 2023
Phase: N/A
Study type: Interventional

This single arm study aims to evaluate the efficacy and safety of a non-surgical approach, consisting of radiotherapy (RT) alone, for patients who have achieved a complete pathological response (pCR) following neoadjuvant chemotherapy (NACT). The study design involves the histological confirmation of pCR using vacuum-assisted biopsy (VABB) or vacuum-assisted excision (VAE) guided by ultrasound. The primary objective is to demonstrate that the non-surgical, RT-only treatment and follow-up approach is not inferior to the traditional surgical approach in patients with pCR after NACT.

NCT ID: NCT06273852 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Start date: April 29, 2024
Phase: Early Phase 1
Study type: Interventional

This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in microdose quantities via the CIVO device.

NCT ID: NCT06264921 Recruiting - Ovarian Cancer Clinical Trials

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Start date: February 23, 2024
Phase: Phase 1
Study type: Interventional

The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Escalation and to determine the preliminary recommended phase 2 dose (RP2D).

NCT ID: NCT06259162 Recruiting - Clinical trials for Triple Negative Breast Cancer

LAG3 Expression in Triple Negative Breast Cancer

Start date: November 18, 2022
Phase: N/A
Study type: Interventional

This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.

NCT ID: NCT06246968 Recruiting - Breast Cancer Clinical Trials

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Start date: January 29, 2024
Phase: Phase 1
Study type: Interventional

Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.

NCT ID: NCT06245889 Recruiting - Clinical trials for Triple Negative Breast Cancer

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

NeoADAPT
Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after 1 cycle of therapy. A breast MRI will be performed after treatment completion. Patients with complete clinical response will proceed to surgery. Patients with clinical residual disease will complete neoadjuvant rescue with 4 cycles of doxorubicin/cyclophosphamide prior to surgery. If residual disease identified after surgery, adjuvant therapy to be determined by the treating oncologist (may include doxorubicin/cyclophosphamide/pembrolizumab, capecitabine etc).

NCT ID: NCT06238479 Recruiting - Prostate Cancer Clinical Trials

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Start date: March 5, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

NCT ID: NCT06224387 Recruiting - Clinical trials for Non-small Cell Lung Cancer

CTS2190 Phase I /II Clinical Study in Patients

Start date: June 26, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types. The study drug, CTS2190, is a PRMT1 inhibitor administered orally. The study is planned to treat up to 224 participants.